Trial Profile
A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE study) )
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Fostemsavir (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms BRIGHTE
- Sponsors Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; ViiV Healthcare
- 12 Dec 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 18 Oct 2023 According to a ViiV Healthcare media release, data from this study will be presented at the 19th Annual European AIDS Conference (EACS 2023)
- 26 Sep 2023 Results of 240-week efficacy and safety of fostemsavir + OBT in adults with multidrug-resistant human immunodeficiency virus , published in the Infectious Diseases and Therapy